ImpriMed Korea

Find the best drugs for treating cancer
‍BEFORE treatment begins

We use functional assays and artificial intelligence to provide personalized predictions on survival and response.

ImpriMed Korea

Find the best drugs for treating cancer
‍BEFORE treatment begins

We use functional assays and artificial intelligence to provide personalized predictions on survival and response.

ImpriMed Korea

Find the best drugs for treating cancer
‍BEFORE treatment begins

We use functional assays and artificial intelligence to provide personalized predictions on survival and response.

ImpriMed Korea

Find the best drugs for treating cancer
‍BEFORE treatment begins

We use functional assays and artificial intelligence to provide personalized predictions on survival and response.

Technology

We analyze traits of each patient’s cancer cells to predict his or her survival and response specific to the choice of chemotherapeutic regimen. The predictive information can help to identify an optimal treatment for each patient.

Human Oncology Pipeline

Precision medicine services for individual blood cancer patients and CRO services for pharmaceutical companies screening a successful drug candidate

STAGE

R&D

COMMERCIAL

Service

Indication/Type

Tech Development

Clinical Study

Innovative Tech Approval

Approval

Sales

IMK-DS

Leukemia (AML, ALL) treatment selection

IMK-MM

Multiple myeloma (MM) treatment selection

IMK-RA

Rheumatoid arthritis treatment selection

IMK-CRO

Drug candidate evaluation AI solution

IMK-DS

Leukemia (AML, ALL) treatment selection

IMK-MM

Multiple myeloma (MM) treatment selection

IMK-RA

Rheumatoid arthritis treatment selection

IMK-CRO

Drug candidate arthritis treatment selection

IMK-DS

Leukemia (AML, ALL) treatment selection

IMK-MM

Multiple myeloma (MM) treatment selection

IMK-RA

Rheumatoid arthritis treatment selection

IMK-CRO

Drug candidate evaluation AI solution

Current

Plan by 2025

New service

Personalized Prediction Profile for Canine Lymphoma and Leukemia

We measure how your dog's live cancer cells respond to different anticancer drugs. Then we use artificial intelligence (AI) to combine these measurements with other biological information to predict which drugs are most likely to be effective for your dog's lymphoma or leukemia.

Our mission is to empower clinicians and help patients with the best predictive information for personalized cancer care.

Our Milestones

2018

Opened ImpriMed Korea office
Received seed funding

2019

Received the Korean Venture Accreditation
Admitted to the Seoul Startup Hub

2020

Acquired IRB approval for the R&D on precision medicine technology for human blood cancer
Received a research grant ($370,000) from the Seoul Business Administration

2021

Won 4th place in the AI model development national competition held by the Ministry of Science and ICT in Korea
Received the research grant ($280,000) from the National Industry Promotion Agency
Nominated as one of the Top 100 Korean AI start-ups
Filed 3rd patent titled Predicting Clinical Outcome or Prognosis of Cancer Treatment based on Machine Learning
Received a research grant ($80,000) from the National Research Foundation of Korea

2022

Signed MOU with The Catholic University Seoul St. Mary's Hospital
Selected to the Mayo Clinic Platform Accelerate Program 2022
Presented our AI precision medicine technology for newly diagnosed multiple myeloma patients at the International Myeloma Society 2022

2023

Published an article about NDMM-1 in Nature Portfolio(npj) Precision Oncology
Relocated ImpriMedKorea’s office and research facilities to DMC Hi-Tech Business Center
Launched the IMV services for canine lymphoma and leukemia
Was nominated as one of the Top 100 Korean AI start-ups for 2023
IMV kit designated as an innovative product by the South Korean Public Procurement Service (PPS)
NDMM-1, designated as an innovative medical device by the South Korean Ministry of Food and Drug Safety (MFDS)

2024

Obtained In Vitro Diagnostic Medical Devices manufacturing permission from the South Korean Ministry of Food and Drug Safety (MFDS)
Presented our scientific poster at European Alliance of Associations for Rheumatology
Presented our abstract and scientific poster at World Veterinary Cancer Congress Tokyo 2024
K-GMP certified in manufacturing of In Vitro Diagnostics (IVD) Software

Today

ImpriMed is bringing together our expertise in humans and canines to accelerate the development of AI-driven personalized medicine solutions for all cancer patients.